The new era of precision medicine in hepatocellular carcinoma: the urgent need for promising biomarkers.
作者信息
Takeda Haruhiko, Nishikawa Hiroki, Osaki Yukio
机构信息
Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan.
出版信息
Hepatobiliary Surg Nutr. 2018 Dec;7(6):490-491. doi: 10.21037/hbsn.2018.08.06.
Abstract
摘要
相似文献
1
The new era of precision medicine in hepatocellular carcinoma: the urgent need for promising biomarkers.肝细胞癌精准医学的新时代：对有前景生物标志物的迫切需求。
Hepatobiliary Surg Nutr. 2018 Dec;7(6):490-491. doi: 10.21037/hbsn.2018.08.06.
2
The application of proteomics in different aspects of hepatocellular carcinoma research.蛋白质组学在肝细胞癌研究不同方面的应用。
J Proteomics. 2016 Aug 11;145:70-80. doi: 10.1016/j.jprot.2016.03.050. Epub 2016 Apr 9.
3
Novel biomarkers in hepatocellular carcinoma.肝细胞癌的新型生物标志物。
Dig Liver Dis. 2018 Nov;50(11):1115-1123. doi: 10.1016/j.dld.2018.08.019. Epub 2018 Aug 24.
4
Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer.非小细胞肺癌免疫检查点阻断治疗中的精准医学
Clin Transl Med. 2017 Dec;6(1):7. doi: 10.1186/s40169-017-0136-7. Epub 2017 Jan 20.
5
Precision Transplant Medicine: Biomarkers to the Rescue.精准移植医学：生物标志物来拯救。
J Am Soc Nephrol. 2018 Jan;29(1):24-34. doi: 10.1681/ASN.2017010004. Epub 2017 Oct 9.
6
The status of transarterial chemoembolization treatment in the era of precision oncology.精准肿瘤学时代的经动脉化疗栓塞治疗现状
Hepat Oncol. 2017 Apr;4(2):55-63. doi: 10.2217/hep-2017-0009. Epub 2017 Sep 26.
7
[Towards precision medicine in myeloma: new evidence and challenges].迈向骨髓瘤精准医学：新证据与挑战
Medicina (B Aires). 2017;77(3):222-226.
8
[Precision nutrition in the era of precision medicine].[精准医学时代的精准营养]
Zhonghua Yu Fang Yi Xue Za Zhi. 2016 Dec 6;50(12):1036-1042. doi: 10.3760/cma.j.issn.0253-9624.2016.12.004.
9
Ductal Carcinoma in Situ Biomarkers in a Precision Medicine Era: Current and Future Molecular-Based Testing.精准医学时代的导管原位癌生物标志物：当前和未来基于分子的检测。
Am J Pathol. 2019 May;189(5):956-965. doi: 10.1016/j.ajpath.2018.08.020. Epub 2018 Oct 29.
10
Five critical elements to ensure the precision medicine.确保精准医疗的五个关键要素。
Cancer Metastasis Rev. 2015 Jun;34(2):313-8. doi: 10.1007/s10555-015-9555-3.
引用本文的文献
1
Addition of trastuzumab emtansine (T-DM1) in a human epidermal growth factor receptor 2-overexpressed metastatic carcinoma of the gallbladder patient to enhance survival: A case study.在一名人表皮生长因子受体2过表达的转移性胆囊癌患者中添加曲妥珠单抗偶联物（T-DM1）以提高生存率：一项病例研究。
SAGE Open Med Case Rep. 2022 Nov 27;10:2050313X221137447. doi: 10.1177/2050313X221137447. eCollection 2022.
2
Role of and as Prognostic Biomarkers for Hepatocellular Carcinoma.[具体物质名称]和[具体物质名称]作为肝细胞癌预后生物标志物的作用。 （原文中“Role of and ”部分内容缺失，以上是根据格式要求补充完整后的译文示例，实际需根据完整原文准确翻译）
Int J Gen Med. 2021 Dec 1;14:9247-9260. doi: 10.2147/IJGM.S337769. eCollection 2021.
3
Programmed cell death protein 1/programmed death ligand-1 checkpoint blockade meets patient-derived organoids.程序性细胞死亡蛋白1/程序性死亡配体1检查点阻断与患者来源的类器官相结合。
Ann Transl Med. 2019 Dec;7(Suppl 8):S287. doi: 10.21037/atm.2019.11.76.
4
Precision oncology for gallbladder cancer: insights from genetic alterations and clinical practice.胆囊癌的精准肿瘤学：来自基因改变和临床实践的见解
Ann Transl Med. 2019 Sep;7(18):467. doi: 10.21037/atm.2019.08.67.
5
Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.晚期肝细胞癌系统治疗的药物遗传学。
World J Gastroenterol. 2019 Aug 7;25(29):3870-3896. doi: 10.3748/wjg.v25.i29.3870.
本文引用的文献
1
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.乐伐替尼与索拉非尼用于不可切除肝细胞癌患者一线治疗的比较：一项随机、III 期非劣效性试验。
Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1.
2
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib.瑞戈非尼和乐伐替尼开启肝细胞癌系统治疗新时代。
Liver Cancer. 2017 Jun;6(3):177-184. doi: 10.1159/000462153. Epub 2017 Mar 9.
3
Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing.通过靶向深度测序对肝细胞癌患者循环游离DNA中的肿瘤相关突变进行无创检测。
Oncotarget. 2016 Jun 28;7(26):40481-40490. doi: 10.18632/oncotarget.9629.
4
Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib.索拉非尼治疗的不可切除肝细胞癌患者细针穿刺活检FFPE标本的靶向DNA和RNA测序
Oncotarget. 2015 Aug 28;6(25):21636-44. doi: 10.18632/oncotarget.4270.
5
FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma.索拉非尼治疗肝细胞癌应答者中 FGF3/FGF4 扩增和多发肺转移。
Hepatology. 2013 Apr;57(4):1407-15. doi: 10.1002/hep.25956. Epub 2013 Feb 11.
Zotero 插件